University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Public Health Resources

Public Health Resources

2006

Sensitivity of Second-Generation Enzyme Immunoassay for
Detection of Hepatitis C Virus Infection among Oncology Patients
Alexandre Macedo de Oliveira
Epidemic Intelligence Service, State Branch, Division of Applied Public Health Training, Epidemiology
Program Office, Centers for Disease Control and Prevention

Kathryn L. White
Nebraska Health and Human Services System

Brady D. Beecham
Nebraska Health and Human Services System

Dennis P. Leschinsky
Nebraska Health and Human Services System

Brett P. Foley
Nebraska Health and Human Services System
See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources
Part of the Public Health Commons

de Oliveira, Alexandre Macedo; White, Kathryn L.; Beecham, Brady D.; Leschinsky, Dennis P.; Foley, Brett P.;
Dockter, Janel; Giachetti, Cristina; and Safranek, Thomas J., "Sensitivity of Second-Generation Enzyme
Immunoassay for Detection of Hepatitis C Virus Infection among Oncology Patients" (2006). Public
Health Resources. 59.
https://digitalcommons.unl.edu/publichealthresources/59

This Article is brought to you for free and open access by the Public Health Resources at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Alexandre Macedo de Oliveira, Kathryn L. White, Brady D. Beecham, Dennis P. Leschinsky, Brett P. Foley,
Janel Dockter, Cristina Giachetti, and Thomas J. Safranek

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/59

Journal of Clinical Virology 35 (2006) 21–25

Sensitivity of second-generation enzyme immunoassay for detection
of hepatitis C virus infection among oncology patients
Alexandre Macedo de Oliveira a,b,∗ , Kathryn L. White b , Brady D. Beecham b ,
Dennis P. Leschinsky b , Brett P. Foley b , Janel Dockter c ,
Cristina Giachetti c , Thomas J. Safranek b
a

Epidemic Intelligence Service, State Branch, Division of Applied Public Health Training, Epidemiology Program Ofﬁce,
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
b Nebraska Health and Human Services System, Lincoln, Nebraska, 301 Centennial Mall South, Lincoln, NE 68509, USA
c Gen-Probe Incorporated, 10210 Genetic Center Drive, San Diego, CA 92121, USA
Received 19 January 2005; received in revised form 14 March 2005; accepted 21 March 2005

Abstract
Background: The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity
and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology
patients is unknown.
Objective: Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during
2000–2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards.
Study design: Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA
2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron
RIBA® HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT)
levels were determined in EIA 2-negative/TMA-positive samples.
Results: A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott
EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (p = 0.01) and poor sensitivity was associated with
receipt of chemotherapy during the outbreak period (p = 0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT.
Conclusions: In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent
persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate
that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA.
© 2005 Elsevier B.V. All rights reserved.
Keywords: Hepatitis C virus; Sensitivity; Immunosuppression; Oncology; Chemotherapy

1. Introduction
Enzyme immunoassays (EIAs), both second- and thirdgenerations, are antibody-detection tests recommended for
Abbreviations: ALT, alanine aminotransferase; CIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; HCV, hepatitis C virus;
NAT, nucleic acid testing; PCR, polymerase chain reaction; RIBA, recombinant immunoblot assay; TMA, transcription-mediated amplification
∗ Corresponding author. Present address: Centers for Disease Control and
Prevention, 4770 Buford Hwy, MS F-22, Atlanta, GA 30341, USA.
E-mail address: acq7@cdc.gov (A. Macedo de Oliveira).
1386-6532/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.jcv.2005.03.006

diagnosing hepatitis C virus (HCV) infection in the United
States (Alter et al., 2003). Since these tests depend on antibody levels at or above test detection limits, sensitivity among
persons with low antibody levels because of recent infection
or immunosupression may be decreased. In addition, antibody tests do not distinguish active infection, characterized
by the presence of HCV ribonucleic acid (RNA) detected
by nucleic acid testing (NAT), from resolved infection
(Erensoy, 2001). Because of the possibility of EIA–falsepositive results, more specific tests (e.g., recombinant
immunoblot assay [RIBA] and NAT) are recommended to
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confirm positive results. EIA-negative results are considered
final and no additional tests are recommended unless recent
infection is suspected or in immunosuppressed persons when
other evidence of HCV infection (e.g., elevated alanine
aminotransferase [ALT] level) exists (Alter et al., 2003).
Previous studies have shown poor EIA sensitivity among
persons undergoing hemodialysis and transplant recipients,
because of the immunosuppression associated with these
conditions (Feucht et al., 1995; Schneeberger et al., 1998;
Pawlotsky, 1999). For these patients, HCV infection diagnosis can be made using a combination of NAT and EIA.
NAT includes qualitative and quantitative reverse transcriptase polymerase chain reaction (PCR) and the newly
developed transcription-mediated amplification (TMA)
assay (Giachetti et al., 2002; Gorrin et al., 2003). Despite
some reports of HCV EIA poor performance in oncology
patients, its sensitivity in this group of persons remains
unknown (Paydas et al., 2003). In this study, we evaluated
the sensitivity of a second-generation EIA (EIA 2) to detect
HCV infection in oncology patients.

2. Methods
2.1. Subject selection
We invited oncology patients from a hematology/oncology clinic in eastern Nebraska to take part
in this study. During March 2000–June 2001, an HCV
outbreak occurred at this clinic due to cross-contamination
of shared saline bags (Centers for Disease Control and
Prevention, 2003; Macedo de Oliveira et al., 2005). Variables potentially associated with antibody-detection tests
performance such as sex, age, type of cancer and receipt of
chemotherapy during the outbreak period were collected
from clinic medical records.

(Carithers et al., 2000). In samples with two Abbott EIA 2positive repeats, HCV infection was confirmed using qualitative PCR (Cobas AmplicorTM HCV Test, v2.0; Roche Molecular Diagnostic Systems, Branchburg, New Jersey) or, in case
of qualitative PCR-negative samples, RIBA (Chiron RIBA®
HCV 3.0 SIA, Chiron Corporation, Emeryville, California).
2.4. TMA testing
We tested all samples using TMA (Gen-Probe Incorporated, San Diego, California). This assay involves three steps
within a single tube: sample preparation with target capture,
HCV RNA target amplification by TMA and detection of the
amplification products by hybridization. For verification purposes, an internal control is added to each reaction (Giachetti
et al., 2002).
2.5. Abbott EIA 2-negative / TMA-positive samples
We further tested the Abbott EIA 2-negative /TMApositive specimens using enhanced chemiluminescence
immunoassay (CIA) (Vitros® Anti-HCV Assay, OrthoClinical Diagnostics, Raritan, New Jersey). This test is one
of the third-generation HCV immunoassays, which have
reported sensitivity of at least 97% (Colin et al., 2001).
For these samples, we confirmed the TMA results using
quantitative PCR (Cobas AmplicorTM HCV Monitor Test,
v2.0; Roche Molecular Diagnostic Systems, Branchburg,
New Jersey) and determined serum ALT levels (Roche
Diagnostics Corporation, Indianapolis, Indiana).
2.6. Case deﬁnition
HCV infection was defined as a positive RIBA or TMA
test in an oncology patient.
2.7. Statistical analysis

2.2. Sample collection
Blood was collected in October 2002, 16 months after the
end of the outbreak, which is beyond the seronegative window period for HCV EIA. After blood collection in 7 mL
SST Vacutainers® , serum was separated by centrifugation
within 4 h. We aliquoted the serum in 2 mL tubes and stored at
−20 ◦ C until processing. All specimen handling and testing
were performed in accordance with manufacturer’s guidelines, as described below.

We used the z-test to compare Abbott EIA 2 sensitivity
with previous reports in the literature. Abbott EIA 2 sensitivity was also stratified by sex, age, type of cancer and use of
chemotherapy during the outbreak period and was evaluated
using the Fisher exact and the chi square tests, as appropriate.

3. Results
3.1. Subject demographics

2.3. Serological testing
HCV serological testing was done using EIA 2 (Abbott
HCV EIA 2.0, Abbott Laboratories, Abbott Park, Illinois).
This assay consists of a microtiter plate with viral antigens
embedded in the wells. Antibodies present in patients’ sera
adhere to the well and anti-immunoglobulins containing a
colorimetric marker are added to allow antibody detection

Of the 472 patients seen at the clinic during the outbreak
period, 269 (57%) oncology patients agreed to be tested. Five
of those were excluded from analysis: three with previous
HCV treatment, one with insufficient material for complete
testing and one with indeterminate laboratory results. Among
the 264 patients included in the analysis, the mean age was 67
years and 183 (69%) were females. The most common cancer
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tive PCR-negative. In these two cases, we confirmed the EIA
2-positive result by RIBA.
3.3. Abbott EIA 2-negative/TMA-positive samples
To exclude the possibility of TMA false positivity, the 16
Abbott EIA 2-negative/ TMA-positive samples were retested
with quantitative PCR and all yielded positive results. Four
(25%) of these samples were CIA-positive. We determined
ALT levels in these 16 specimens, and 15 (94%) were within
the normal range (<31 IU/mL).
3.4. Abbott EIA 2 sensitivity

Fig. 1. Laboratory results of valid specimens included in the analysis
(n = 264), Nebraska 2000–2001.

diagnosis was breast cancer (114 [43%] patients), followed
by colon cancer (55 [21%] patients) and leukemia/lymphoma
(37 [14%] patients). One hundred and two (39%) patients
received chemotherapy during the outbreak period.
3.2. HCV test results
We identified 92 (35%) cases among the 264 valid samples. Seventy-four cases were positive by Abbott EIA 2, qualitative PCR and TMA, and 16 cases were Abbott EIA 2negative and TMA-positive (Fig. 1). Additionally, two of the
92 cases were EIA 2-positive, TMA-negative and qualita-

In this study, Abbott EIA 2 sensitivity was 83% (76/92),
lower than that in previous studies (90%), which were based
on immunocompetent persons (p = 0.01) (Whyte and Beal,
1995). All 16 Abbott EIA 2–false-negative results were
seen among patients who received chemotherapy during the
outbreak period. The difference in Abbott EIA 2 sensitivity
between patients receiving and not receiving chemotherapy
during the outbreak period (78% versus 100%, respectively)
was statistically significant (p = 0.02) (Table 1). Abbott EIA
2 sensitivity did not statistically differ when stratified by
sex, age, or type of cancer.

4. Discussion
Abbott EIA 2 sensitivity was estimated at 83% among
oncology patients from a Nebraska clinic where an
HCV outbreak occurred (Centers for Disease Control and
Prevention, 2003; Macedo de Oliveira et al., 2005). The 16
patients with Abbott EIA 2–false-negative results had HCV
infection demonstrated by NAT. Previous studies have shown
lower sensitivity of HCV EIA in persons immunosuppres-

Table 1
Abbott EIA 2 sensitivity stratified by age, sex, type of cancer and use of chemotherapy, Nebraska 2000–2001
Risk factor

Number of Abbott EIA 2-positive results

Number of cases

Sensitivity (%)

Age
<61 yr.
61–74 yr.
>74 yr.

28
29
19

33
34
25

85
85
76

Sex
Female
Male

43
33

56
36

77
92

Type of cancer
Breast cancer
Colon cancer
Leukemia/lymphoma
Other cancer

24
20
13
19

29
27
17
19

83
74
76
100

Chemotherapy
Yes
No

56
20

72
20

78
100

Yr. = years.

p-Value
0.65

0.09

0.12

0.02
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sion due to hemodialysis and organ transplantation, cases of
acute HCV infection and infants born to HCV-infected mothers (Bukh et al., 1993; Soffredini et al., 2004). However, few
studies have assessed the sensitivity of HCV immunoassays
among patients with cancer or receiving chemotherapy.
The present study indicates that EIA 2 sensitivity in oncology patients is lower than that reported among immunocompetent persons (Whyte and Beal, 1995; Abdel-Hamid et al.,
2002). A more sensitive immunoassay, CIA, was positive in
4 (25%) of the 16 EIA 2–false-negative cases. EIA 2-positive
samples (n = 76) were not tested by CIA, but assuming that all
these cases were also CIA-positive, we can estimate a maximum CIA sensitivity of 87% (80/92). This performance is
below the sensitivity of third-generation HCV immunoassays
among immunocompetent persons and HIV-infected patients
(>99%) (Abdel-Hamid et al., 2002; Thio et al., 2000). One
limitation inherent in the analysis of HCV test sensitivity is
the lack of a consensus regarding the gold standard for HCV
infection (Pawlotsky, 1999). In this investigation, we used a
combination of serological (RIBA) and NAT (TMA) assays
as the gold standards, a strategy adopted in previous studies
(Janot et al., 1994; Colin et al., 2001).
Decreased EIA 2 sensitivity was associated with receipt
of chemotherapy. We were unable to distinguish the relative contributions of cancer and chemotherapy to decreased
EIA 2 sensitivity because all false-negative results were seen
among patients undergoing chemotherapy and few patients
without chemotherapy exposure (n = 20) were available for
comparison. Future studies documenting HCV-antibody response among oncology patients are needed. Sex, age and
type of cancer were not significantly associated with EIA
2 performance; however, our study might have lacked the
power to find such association if it existed.
Cancer and its treatment may cause cellular and humoral
immune deficiencies, but the impact on HCV EIA performance is unknown. Previous reports have shown reduced EIA
sensitivity for diagnosing adenovirus infection among bone
marrow transplant recipients (Raboni et al., 2003). Additionally, other studies have shown decreased vaccine-induced antibody levels after chemotherapy and recommended patient
revaccination (Reinhardt et al., 2003). It follows that among
oncology patients, cancer- and/or chemotherapy-induced immunosupression might have contributed to low levels of HCV
antibodies and the reduced EIA sensitivity seen in our study.
Three generations of HCV immunoassays have been developed to detect circulating HCV antibodies. The firstgeneration HCV EIA was developed in 1989 but had poor
sensitivity and specificity (Baath et al., 1992). The secondand third-generation assays improved sensitivity to 90%
and 97%, respectively, and are equally recommended as
screening tests in the United States (Whyte and Beal, 1995;
Abdel-Hamid et al., 2002; Colin et al., 2001). According to
current guidelines, EIA-negative results are considered final,
except when recent infection is suspected or in immunosuppressed persons with a high index of suspicion for HCV infection, such as abnormal ALT levels (Alter et al., 2003). In

this study, 15 (94%) of the 16 Abbott EIA 2–false-negative
cases had ALT levels within the normal range and would have
gone undiagnosed if NAT had not been performed. We recognize that, based on previously published reports, clinicians already employ a combination of EIA and NAT testing to assess
HCV status in oncology patients (Paydas et al., 2003). However, because of the limited number of study subjects, these
reports could not offer definitive conclusions about EIA sensitivity and appropriate testing algorithms within this patient
population.
In summary, our study suggests that EIA sensitivity among
oncology patients is low, which limits the role of this assay as
a screening test. The ultimate importance of HCV testing is
to identify patients with active infection, i.e. circulating HCV
RNA, and provide treatment. However, exclusive use of NAT
is also suboptimal, because it will not identify patients with
resolved HCV infection (EIA-positive and NAT-negative patients), who should be identified, regularly monitored and
treated if their disease recrudesces (Lauer et al., 2001). Therefore, both EIA and NAT should be routinely performed in all
oncology patients when assessing HCV status.
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